<DOC>
	<DOCNO>NCT00796549</DOCNO>
	<brief_summary>The primary objective open-label , single arm Phase II trial explore efficacy BIBW 2992 define objective response rate ( CR , PR ) determine RECIST criterion patient EGFR FISH positive advance NSCLC Stage IIIB IV , select accord follow scheme : - Forty ( 40 ) 1st line patient - Thirty ( 30 ) 2nd line patient Patients enter trial treat follow death lose follow-up . Additional information obtain safety profile PK analysis BIBW 2992 .</brief_summary>
	<brief_title>BIBW2992 ( Afatinib ) Advanced ( EGFR-FISH + ) NSCLC ( Non Small Cell Lung Cancer ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age &gt; 18 year . 2 . Patients pathologically confirm diagnosis NSCLC Stage IIIB ( pleural effusion ) Stage IV histopathological classification adeno bronchoalveolar carcinoma ( BAC ) . 3 . Increased EGFR gene copy number assess FISH analysis . After sign informed consent , positive result EGFR FISH determination mandatory proceed screen assessment . 4 . At least one tumour lesion accurately measure compute tomography ( CT ) magnetic resonance imaging ( MRI ) least one dimension long diameter record 20 mm use conventional technique moro 10 mm spiral CT scan . 5 . Patients previously expose chemotherapy NSCLC ( 1st line patient , 40 total ; subject adjuvant chemotherapy allow least 12 month elapse since last course treatment ) , patient relapse one systemic treatment ( 2nd line patient , 30 total ; le 12 month elapse since adjuvant chemotherapy , patient 2nd line one , adjuvant chemotherapy must consider line treatment ) . 6 . Life expectancy least three ( 3 ) month . 7 . Eastern Cooperative Oncology Group ( ECOG , R010787 ) performance score 0 , 1 2 . 8 . Written inform consent consistent ICHGCP guideline . Exclusion criterion : 1 . More two ( 2 ) prior cytotoxic chemotherapy treatment regimen relapse metastatic NSCLC , include adjuvant chemotherapy relapse occur less 12 month 2 . Previous treatment erlotinib ( Tarceva® ) , gefitinib ( Iressa® ) EGFR inhibit small molecule antibody . 3 . Active brain metastasis ( stable &lt; 4 week , symptomatic , require treatment anticonvulsant , leptomeningeal disease ) . Dexamethasone therapy allow administer stable dose least one month randomization . 4 . Chemo , hormone ( megestrol acetate steroid require maintenance noncancer therapy ) immunotherapy within past 4 week first drug administration . 5 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g. , Crohn disease , malabsorption , CTCAE Grade &gt; 2 diarrhea etiology baseline 6 . Patients lifethreatening illness organ system dysfunction , opinion investigator , would either compromise patient safety interfere evaluation safety test drug . 7 . Other malignancy diagnose within past five ( 5 ) year ( non melanomatous skin cancer situ cervical cancer ) . 8 . Radiotherapy within past 2 week prior treatment trial drug . 9 . Patients serious active infection ( i.e. , require IV antibiotic , antifungal , antiviral agent ) . 10 . Patients know HIV , active hepatitis B active hepatitis C. 11 . Known suspected active drug alcohol abuse . 12 . Women childbearing potential men able father child unwilling use medically acceptable method contraception trial . 13 . Pregnancy breast feed . 14 . Patients unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>